CHUGAI SEIYAKU KABUSHIKI KAISHA

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
C07K PEPTIDES 20915
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 19786
 
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 63143
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 62105
 
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 4852
 
 
 
C07D HETEROCYCLIC COMPOUNDS 44118
 
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 3663
 
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 18120
 
 
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 14111
 
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 1184

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0016,327 A Combination of Two or More Anti-C5 Antibodies and Methods of UseJan 22, 16Jan 18, 18[A61K, C07K]
2018/0016,576 Novel Therapeutic Agent for Septicemia, and a Method for Screening for SameDec 22, 15Jan 18, 18[C12Q, C12N, C07K]
2018/0000,779 COMBINATION DRUGJan 15, 16Jan 04, 18[A61K]
2018/0002,396 NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR10Sep 15, 17Jan 04, 18[A61K, C07K]
2018/0002,415 ANTI-C5 ANTIBODIES AND METHODS OF USEAug 28, 17Jan 04, 18[A61K, G01N, C07K]
2018/0002,443 ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIIISep 12, 17Jan 04, 18[C07K]
2017/0362,304 METHOD FOR MEASURING VISCOSITY OF PROTEIN SOLUTIONAug 20, 15Dec 21, 17[G01N, C07K]
2017/0342,133 sc(Fv)2 SITE-DIRECTED MUTANTMay 15, 17Nov 30, 17[C07K]
2017/0283,483 METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIESApr 19, 17Oct 05, 17[C07K]
2017/0275,332 POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERSJun 08, 17Sep 28, 17[C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9920129 Diagnosis and treatment of cancer using anti-ITM2A antibodyApr 29, 16Mar 20, 18[G01N, C07K]
9902777 Methods for producing subtypes of humanized antibody against interleukin-6 receptorAug 26, 15Feb 27, 18[A61K, C12P, C07K]
9890218 Heterodimerized polypeptideJun 29, 12Feb 13, 18[G01N, C07K]
9890377 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyMay 08, 13Feb 13, 18[A61K, C12N, G01N, C07K]
9868948 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyMay 08, 13Jan 16, 18[A61K, C12N, G01N, C07K]
9828429 Method of modifying isoelectric point of antibody via amino acid substitution in CDRJun 17, 15Nov 28, 17[A61K, G01N, C07K]
9828619 Methods for producing polypeptides by regulating polypeptide associationMar 31, 06Nov 28, 17[A61K, C12P, C07K]
9814776 Pharmaceutical preparation comprising aminopyrazole derivativeJul 31, 14Nov 14, 17[A61K, C07C]
9802993 Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexateOct 14, 08Oct 31, 17[C12P, C07K]
9777066 Pharmaceutical compositions containing sc(Fv)2Dec 14, 15Oct 03, 17[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0145,111 Antibody Substituting for Function of Blood Coagulation Factor VIIIAbandonedJan 10, 17May 25, 17[C07K]
2017/0022,278 PREVENTIVE OR THERAPEUTIC AGENT FOR SENSITIZED T CELL-MEDIATED DISEASES COMPRISING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENTAbandonedMay 09, 16Jan 26, 17[C07K]
2016/0326,175 HYDANTOIN DERIVATIVEAbandonedJul 20, 16Nov 10, 16[C07D]
2016/0194,401 THERAPEUTIC AGENT FOR CHRONIC ARTHRITIDES DISEASES OF CHILDHOOD-RELATED DISEASESAbandonedJan 04, 16Jul 07, 16[A61K, C07K]
2016/0053,019 MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOFAbandonedSep 09, 15Feb 25, 16[C07K]
2016/0022,812 THERAPEUTIC AGENTS FOR PANCREATIC CANCERAbandonedOct 08, 15Jan 28, 16[A61K]
2015/0315,278 Anti-Glypican-3 Antibody Having Improved Kinetics in PlasmaAbandonedFeb 24, 15Nov 05, 15[C07K]
2015/0246,965 Pharmaceutical Composition Comprising Anti-HB-EGF Antibody as Active IngredientAbandonedMar 09, 15Sep 03, 15[A61K, C07K]
2015/0191,540 PREVENTIVE OR THERAPEUTIC AGENT FOR SENSITIZED T CELL-MEDIATED DISEASES COMPRISING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENTAbandonedMar 18, 15Jul 09, 15[C07K]
2015/0010,554 METHODS FOR TREATING INTERLEUKIN-6 RELATED DISEASESAbandonedSep 24, 14Jan 08, 15[A61K]
2014/0377,254 SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTORAbandonedApr 14, 14Dec 25, 14[C07K]
2014/0370,018 MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOFAbandonedSep 05, 13Dec 18, 14[C07K]
2014/0302,511 CANCER STEM CELL-SPECIFIC MOLECULEAbandonedOct 26, 12Oct 09, 14[C12Q, G01N, C07K]
2014/0271,868 TREATMENT OF ACHONDROPLASIA WITH ENCAPSULATED CNP-SECRETING CELLSAbandonedApr 17, 14Sep 18, 14[A61K]
2014/0193,420 DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ITM2A ANTIBODYAbandonedApr 18, 12Jul 10, 14[G01N, C07K]
2014/0079,695 PREVENTIVE AGENT FOR VASCULITISAbandonedNov 22, 13Mar 20, 14[A61K]
2014/0056,883 SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODYAbandonedOct 24, 13Feb 27, 14[A61K]
2014/0037,632 MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOFAbandonedSep 06, 13Feb 06, 14[C07K]
2014/0017,236 METHODS FOR TREATING INTERLEUKIN-6 RELATED DISEASESAbandonedSep 13, 13Jan 16, 14[A61K]
8623360 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyWithdrawnAug 27, 12Jan 07, 14[A61K, C07K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.